Heart and kidney study of SGLT2 inhibitors
Part of Heart & circulation, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at whether a type of diabetes medicine called SGLT2 inhibitors (also known as flozins) can help protect the heart and kidneys in people with both heart failure with preserved pumping function and moderate chronic kidney disease, with or without diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- Your heart's pumping ability (ejection fraction) is greater than 40%.
- You have moderate chronic kidney disease (stage 3 or 4).
- Your doctor has recommended you take an SGLT2 inhibitor (flozin) for your kidney or heart health.
- You do not have severe kidney disease (stage 5), are not on dialysis, and do not have certain serious conditions like active cancer or an unstable heart condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a diabetes medication, called an SGLT2 inhibitor, can reduce inflammation around heart arteries in people who have had a heart attack but do not have diabetes. The study uses a special heart scan to look at changes over time.
This study looks at how a class of diabetes and kidney drugs called SGLT2 inhibitors affect older adults. It aims to understand the benefits for your kidneys and metabolism.
This study tests whether a medicine called an SGLT2 inhibitor (a type of diabetes drug also used for heart failure) affects the heart and blood vessels in people with kidney failure who are on dialysis. It will help doctors understand if this medicine is safe and helpful for dialysis patients.
This study looks at how SGLT2 inhibitor medications (a type of diabetes drug) protect the kidneys in people with type 2 diabetes and chronic kidney disease. Researchers will use MRI scans to understand the protective effects, which could help improve future treatments.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This trial looks at whether a medicine called an SGLT2 inhibitor (a type of diabetes drug) can help protect the kidneys and heart in people with chronic kidney disease or type 2 diabetes. If you have either condition, you might be able to join.
Hear when a new SGLT2 Inhibitors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.